Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AXS vs ACT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–6 Matrix Metrics)

ACT Overall Winner 6-Pillar Tally: AXS 3 – 3 ACT Matrix Metrics: AXS 6 – 4 ACT

As of Nov 16, 2026, Enact Holdings, Inc. (ACT) is the stronger overall head-to-head candidate over Axis Capital Holders Limited (AXS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AXS carries a Unified Composite Score of 38.6/100 (SELL) at $109.99 (8.2x Forward P/E, 18.2% operating margin), whereas ACT carries 43.5/100 (HOLD) at $45.75 (9.1x Forward P/E, 72.5% operating margin).

  • Technical & Structure Timing Caution: AXS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.4); meanwhile ACT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXS vs ACT
AXS NYSE
Axis Capital Holders Limited
Fire, Marine & Casualty Insurance
$109.99
+1.17% 1D
Market Cap $7.8B
TTM Revenue $6.92B
Forward P/E 8.2x
Beta / 30D Vol -0.14β · 20% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 25.0 Fund 41.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.2% over 20 days), RSI 72
RSI-14: 72.4 · SMA20: $105.29 · SMA50: $100.48
ACT NASDAQ Head-to-Head Winner
Enact Holdings, Inc. Common Stock
Insurance Agents, Brokers & Service
$45.75
+0.79% 1D
Market Cap $6.1B
TTM Revenue $1.25B
Forward P/E 9.1x
Beta / 30D Vol 0.01β · 24% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 25.0 Fund 44.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.9%) with fading momentum, RSI 43
RSI-14: 43.1 · SMA20: $47.04 · SMA50: $47.03

6-Pillar Scorecard Institutional Category Breakdown (AXS 3 – 3 ACT)

Columns: Metric · AXS · ACT
1. Valuation Multiples AXS
Forward P/E 8.2x 9.1x
Trailing P/E 8.3x 9.5x
PEG Ratio 1.18x N/M
EV / Revenue 1.1x 5.1x
2. Growth & Scale AXS
Revenue Growth (YoY) +6.9% +0.4%
Earnings Growth (YoY) -26.5% +4.5%
TTM Revenue (USD) $6.92B $1.25B
Market Cap $7.8B $6.1B
3. Profitability & Quality ACT
Gross Margin 28.7% 72.5%
Operating Margin 18.2% 72.5%
Net Profit Margin 14.6% 54.1%
Return on Equity (ROE) 16.0% 12.9%
4. Balance Sheet & Cash Flow ACT
Cash Generation (TTM) $1.32B EBITDA $713M
Cash Flow Margin 19.1% EBITDA Mgn 56.8%
Net Cash / Leverage $79.76 Book/Sh · 16.0% ROE $241M Net Debt (0.14x D/E)
Dividend Yield 1.63% 1.96%
5. Options & Positioning ACT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 18.7% (35th %ile) 39.7% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat AXS
OpEx & R&D Intensity 10.5% of Rev ($727M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Insurance - Specialty Operator Insurance - Specialty Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXS (6) vs ACT (4)
Institutional Metric AXS ACT Criterion Row Edge
Market Capitalization
Scale
$7.8B $6.1B Larger Scale AXS
Trailing P/E Ratio
Valuation
8.3x 9.5x Lower Multiple AXS
Forward P/E Ratio
Valuation
8.2x 9.1x Lower Multiple AXS
Revenue Growth (YoY)
Growth
+6.9% +0.4% Higher Growth AXS
Operating Margin (TTM)
Profitability
18.2% 72.5% Higher Margin ACT
Net Profit Margin
Profitability
14.6% 54.1% Higher Margin ACT
Return on Equity (ROE)
Capital Efficiency
16.0% 12.9% Higher ROE AXS
52-Week Range Position
Momentum
63% ($93–$120) 65% ($37–$51) Stronger Trend ACT
Beta / 30D Volatility
Risk Regime
-0.14β · 20% Vol 0.01β · 24% Vol Lower Realized Risk AXS
Unified Institutional Score
Composite Signal
38.6 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite ACT
Trailing 12M Revenue (USD)
Operating Scale
$6.92B $1.25B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.7% 72.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.18x PEG · 1.1x EV/Rev N/M PEG · 5.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.32B EBITDA ($79.76 Book/Sh · 16.0% ROE) $713M ($241M Net Debt (0.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXS +11.55 pp
AXS: +10.4% · ACT: -1.15%
3M Horizon AXS +17.75 pp
AXS: +9.18% · ACT: -8.57%
6M Horizon AXS +5.41 pp
AXS: +9.29% · ACT: +3.88%
1Y Horizon ACT +14.57 pp
AXS: +7.11% · ACT: +21.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXS vs ACT. Trailing 12-month operating profitability (AXS 18.2% vs ACT 72.5%) and valuation multiples (AXS 8.2x vs ACT 9.1x Forward P/E) are benchmarked directly in Pillar 4 below.

AXS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.92B
Gross Margin28.7%
Op. Margin18.2%
ROE / Fwd P/E16.0% · 8.2x
ACT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.25B
Gross Margin72.5%
Op. Margin72.5%
ROE / Fwd P/E12.9% · 9.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 18.7%
IV Percentile 35th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACT CONSOLIDATION
63d in phase · OBV DISTRIBUTION
Current IV 39.7%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXS Moat Profile Scale & Operating Efficiency Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $7.8B market capitalization and 18.2% operating margin.
OpEx & R&D Reinvestment 10.5% of Rev ($727M)
90D Engineering Disclosures 0 Published
ACT Moat Profile High-Margin Pricing Power Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $6.1B market capitalization and 72.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AXS vs ACT Key Questions & Quantitative Answers

As of Nov 16, 2026, Enact Holdings, Inc. (ACT) is the stronger overall head-to-head candidate over Axis Capital Holders Limited (AXS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). AXS carries a Unified Composite Score of 38.6/100 (SELL) at $109.99 (8.2x Forward P/E, 18.2% operating margin), whereas ACT carries 43.5/100 (HOLD) at $45.75 (9.1x Forward P/E, 72.5% operating margin). Technical & Structure Timing Caution: AXS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.4); meanwhile ACT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AXS leads the Growth & Scale pillar: AXS posts +6.9% YoY revenue growth and -26.5% YoY earnings growth on $6.92B TTM revenue (28.7% gross margin, 18.2% operating margin), compared with ACT at +0.4% YoY revenue growth and +4.5% YoY earnings growth on $1.25B TTM revenue (72.5% gross margin, 72.5% operating margin). On trailing 12-month operating scale, AXS generates $6.92B in USD-normalized revenue versus $1.25B for ACT. In operating R&D and SG&A reinvestment, AXS deploys 10.5% of Rev ($727M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACT.

AXS screens cheaper on headline valuation multiples. AXS trades at 8.2x Forward P/E, 8.3x Trailing P/E, 1.18x PEG, and 1.1x EV/Revenue (19.1% EBITDA margin), whereas ACT trades at 9.1x Forward P/E, 9.5x Trailing P/E, N/M PEG, and 5.1x EV/Revenue (56.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXS (16.0% ROE) versus ACT (12.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AXS carries 18.7% implied volatility (35th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.14β · 20% Vol realized risk). By comparison, ACT carries 39.7% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.01β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.